ArticleCureus2025
Refractory Immune Thrombocytopenic Purpura With Low Immature Platelet Fraction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of immune thrombocytopenic purpura (ITP) remains challenging due to the lack of a "gold standard test," with current approaches relying on clinical evaluation, complete blood count, and peripheral blood smear. The immature platelet fraction (IPF) has emerged as a useful tool for differentiating ITP from hypoproliferative thrombocytopenia, typically presenting as elevated in ITP cases. IPF measures the percentage of immature platelets and is primarily used to help differentiate between thrombocytopenia caused by decreased production, such as bone marrow disorders, and destruction, like ITP. We present a unique case of a 43-year-old woman with severe thrombocytopenia, initially presenting with a platelet count of zero and a low IPF. Despite multiple platelet transfusions and high-dose dexamethasone, her platelet count remained critically low. Bone marrow biopsy findings confirmed ITP, leading to a revised treatment strategy that included intravenous immunoglobulin (IVIG) and rituximab, resulting in sustained platelet recovery. This case underscores the diagnostic and therapeutic challenges associated with ITP, particularly in patients with atypical presentations. The presence of a low IPF complicated initial diagnostic considerations, necessitating a bone marrow biopsy to exclude alternative etiologies such as bone marrow failure. Additionally, patient-specific factors, including diabetes mellitus, chronic pancreatitis, and prior alcohol use disorder, may have contributed to the severity of thrombocytopenia. Our findings highlight the need for individualized diagnostic approaches and tailored treatment strategies in severe and refractory ITP cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.